Technology Transactions and Licensing TRANSACTIONAL

WilmerHale's Technology Transactions and Licensing lawyers leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.


In the highly competitive worlds of biotechnology and information technology, licensing transactions and strategic alliances can make the difference between success and failure. The attorneys in WilmerHale's Technology Transactions and Licensing Practice—many of whom have backgrounds in computer engineering, biochemistry, and other technical fields—collaborate closely with our corporate, licensing, intellectual property, regulatory and tax lawyers to negotiate agreements for clients across a broad spectrum of industries. They handle hundreds of complex joint ventures, strategic alliances, and outsourcing and licensing transactions each year, some of which span international borders. Their work often receives industry commendation for its significance in shaping the future of science and technology.

Contacts

Sort By
Barrett, Steven D.

Steven D. Barrett

Co-Chair, Technology Transactions and Licensing Practice Group

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Barrett, Steven D.

Steven D. Barrett

Partner

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Braun, Martin

Dr. Martin Braun

Partner

+49 69 27 10 78 207 (t)

martin.braun@wilmerhale.com

Finkel, Robert M.

Robert M. Finkel

Partner

+1 212 295 6555 (t)

robert.finkel@wilmerhale.com

Gokhale, Ashwin

Ashwin Gokhale

Partner

+1 650 858 6071 (t)

ashwin.gokhale@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Partner

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Kipnis, Jason

Jason D. Kipnis

Partner

+1 650 600 5036 (t)

jason.kipnis@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Partner

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Gallick_Lawrence_lo

Lawrence Gallick

Senior Associate

+1 650 858 6185 (t)

lawrence.gallick@wilmerhale.com

Experience

We represent market leaders in life sciences, technology, energy and cleantech, communications, financial services and other industries. These companies include: 

  • Cutting-edge biotech developers Agios, Epizyme, Macrogenics, Merrimack, Ophthotech and Vedanta;
  • Gene-therapy innovators Spark Therapeutics and Editas;
  • Pharmaceutical companies Bristol-Myers Squibb and Vertex;
  • Personalized medicine company Kew Group;
  • Consumer electronics companies Bose and TiVo;
  • Data analysis pioneers Cellebrite, Kensho and Thasos;
  • FinTech innovators MineralTree and Qapital, as well as financial services providers American Express and MFS Investment Management;
  • Hardware developers and manufacturers Analog Devices and SanDisk;
  • Software and IT developers Toyota InfoTechnology Center and Progress Software;
  • Telecommunications leaders Altiostar, Broadcom and Cincinnati Bell;
  • Healthcare IT innovator Caradigm;
  • Video game developer Harmonix;
  • Artificial intelligence developer MetaMind Entertainment; and
  • Filmmaking and technology company Wymsee.

Read more about the transactions we've done.

Publications & News

View

June 9, 2017

The Legal 500 United States 2017 Recognizes 125 WilmerHale Lawyers Across 28 Practice Areas

The Legal 500 United States has released its 2017 rankings, recommending 125 WilmerHale lawyers—including 12 who are named to its elite “Leading Lawyers” list and two on its “Next Generation Lawyers” list—and 28 practice areas in its 11th edition.

June 7, 2017

Selected 2017 Strategic Alliances, Joint Venture and Licensing Transactions

Our corporate, licensing, intellectual property and regulatory lawyers regularly handle a broad range of strategic alliance, joint venture, licensing,
collaboration, product development, outsourcing, manufacturing, distribution and similar agreements, including many significant deals that are helping to shape the future of science, technology and commerce.

June 7, 2017

Selected 2017 Technology Transactions

For more than four decades, we have represented technology clients in venture capital financings, public offerings, and mergers and acquisitions; handled their licensing, outsourcing, services, joint venture, development and distribution transactions throughout the world; protected their innovations through patent prosecution, portfolio development and litigation; defended their interests in enterprise-critical litigation; and navigated regulatory issues vital to their success.

May 26, 2017

WilmerHale Lawyers and Practices Recognized in 2017 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2017 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 86 WilmerHale lawyers as leaders in their respective fields.

May 2, 2017

WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.

March 16, 2017

Allergan and Editas Medicine Enter Into Strategic R&D Alliance

The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform.

January 23, 2017

Law360 Names WilmerHale a Technology Group of the Year

The firm has been recognized by Law360 as a Technology Practice Group of the Year, showcasing some of the firm's significant successes for clients during the calendar year of 2016.

December 15, 2016

WilmerHale Reps Spark Therapeutics in Licensing Agreement with Selecta Biosciences

Spark Therapeutics and Selecta Biosciences, Inc. announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology for co-administration with gene therapy targets.

November 17, 2016

Rise of digital DNA raises biopiracy fears

Bruce Manheim is quoted in this article published in Science magazine. The article describes how the use of digital DNA may be regulated by various nations under the Nagoya Protocol and may lead to allegations of biopiracy.

November 11, 2016

WilmerHale Advises Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine in Establishment of Bridge Medicines

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they established a new drug discovery company called Bridge Medicines.

Recognition

  • Best Lawyers in America – Recognized nearly 100 WilmerHale partners in 2016, naming seven as Lawyers of the Year. From 2010-2013, WilmerHale's Technology Law practice received a number one ranking.
  • BioPharm Insight – Consistently lists our attorneys among the leading legal advisors for biotech and pharma licensing agreements in the global, North American and European and Asia-Pacific ranking tables.
  • Chambers Global – Named WilmerHale among the best in the United States in outsourcing in 2014 and 2015.
  • Chambers USA: America's Leading Lawyers for Business – Named the firm in 2016 among the best in Massachusetts in technology, and in 2014 and 2015 among the best in the nation in technology and outsourcing. The "enormously respected" Robert Finkel is recognized for his significant technology experience and "practical approach and negotiation style." He is also named a "thought leader in the sourcing industry" with "unparalleled" industry knowledge.
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016, an award recognizing the firm's key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • LMG Life Sciences Ranked the firm in its 2013-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms serving the life sciences industry. Co-Chairs Steven Barrett and Belinda Juran have also been named "Life Sciences Stars." 
  • Super Lawyers – Named Co-Chair Steven Barrett a "Massachusetts Super Lawyer" in the 2014 edition of Boston Magazine.
  • The Legal 500 United States – Recognized Co-Chair Belinda Juran in 2013 as "a fantastic collaborator" and "outstanding in licensing."
  • U.S. News - Best Lawyers® – In the 2017 "Best Law Firms" rankings, our technology law practice was ranked in the second-tier nationally and in the first-tier in Boston. Our information technology law practice was ranked in the third-tier nationally and second-tier in Boston.
  • Who's Who Legal – Recognized Co-Chair Steven Barrett as a leader in life sciences in the 2015 edition.